DeJarnette hires executive VP

The combination of Philips’ MR 7700 multi-nuclei scanner with the FDA-approved Xenoview hyperpolarized Xenon magnetic resonance imaging (MRI) contrast agent may facilitate earlier diagnosis and intervention for patients with obstructive lung diseases.

Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.

The artificial intelligence (AI)-powered Ezra Flash reportedly enhances magnetic resonance imaging (MRI) and enables significant reductions in scan times and costs for full-body MRI.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

Precision DL, a deep learning-based software which will be available on GE HealthCare’s Omni Legend PET/CT device, reportedly increases the detectability of small, low-contrast lesions by 42 percent.

Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.